تاریخچه درآمد، سود و جریان نقد از صورتهای مالی رسمی.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
نمودارهای تعاملی و صورتهای مالی کامل ← مدل ارزشگذاری (DCF) ←
| صورت سود و زیان | TTM → 2026-03-31 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 | 2018-06-30 | 2017-06-30 | 2016-06-30 | 2015-06-30 | 2014-06-30 | 2013-06-30 | 2012-06-30 | 2011-06-30 | 2010-06-30 | 2009-06-30 | 2008-06-30 | 2007-06-30 | 2006-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| مجموع درآمد | $1.2B | $1.2B | $1.2B | $1.1B | $1.1B | $931M | $739M | $714M | $643M | $563M | $499M | $452M | $358M | $311M | $315M | $290M | $269M | $264M | $257M | $223M | $203M |
| سود ناخالص | $786M | $790M | $770M | $770M | $756M | $633M | $483M | $473M | $432M | $375M | $337M | $307M | $251M | $231M | $236M | $225M | $215M | $208M | $205M | $177M | $157M |
| حاشیه سود ناخالص % | 65.0% | 64.8% | 66.4% | 67.7% | 68.4% | 68.0% | 65.4% | 66.3% | 67.2% | 66.5% | 67.5% | 67.9% | 70.3% | 74.4% | 75.0% | 77.6% | 79.8% | 79.0% | 79.5% | 79.1% | 77.4% |
| سود عملیاتی (EBIT) | $154M | $102M | $207M | $299M | $297M | $237M | $157M | $126M | $136M | $122M | $151M | $147M | $160M | $158M | $166M | $163M | $156M | $151M | $144M | $124M | $109M |
| حاشیه سود عملیاتی % | 12.7% | 8.4% | 17.8% | 26.3% | 26.8% | 25.5% | 21.3% | 17.6% | 21.2% | 21.6% | 30.2% | 32.5% | 44.6% | 51.0% | 52.8% | 56.2% | 58.1% | 57.1% | 56.0% | 55.5% | 53.5% |
| سود خالص | $110M | $73M | $168M | $285M | $272M | $140M | $229M | $96M | $125M | $77M | $104M | $108M | $111M | $113M | $112M | $112M | $110M | $105M | $104M | $85M | $73M |
| حاشیه سود خالص % | 9.0% | 6.0% | 14.5% | 25.1% | 24.6% | 15.1% | 31.0% | 13.5% | 19.5% | 13.7% | 20.9% | 23.8% | 31.0% | 36.2% | 35.7% | 38.7% | 40.8% | 39.9% | 40.2% | 38.1% | 36.2% |
| EBITDA | $258M | $217M | $313M | $457M | $414M | $250M | $378M | $212M | $201M | $182M | $193M | $184M | $179M | $173M | $175M | $174M | $165M | $159M | $152M | $137M | $115M |
| سود هر سهم (EPS) | $0.70 | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 | $1.45 | $0.62 | $0.82 | $0.52 | $0.70 | $0.72 | $0.75 | $0.76 | $0.76 | $0.76 | $0.73 | $0.69 | $0.66 | $0.54 | $0.46 |
| سهام منتشرشده (میلیون) | 157M | 160M | 161M | 162M | 164M | 162M | 158M | 156M | 152M | 150M | 149M | 149M | 148M | 148M | 148M | 149M | 149M | 152M | 157M | 158M | 158M |
منبع: گزارشهای عمومی شرکت (SEC). پیش از اتکا به هر رقم، آن را در SEC EDGAR بررسی کنید.
ترازنامهها، جریانهای نقدی، دادههای فصلی و نسبتهای مالی کامل در نمایشگر تعاملی TECH در دسترس است. /companies/us/TECH
اطلاعات این وبسایت صرفاً برای اهداف آموزشی و اطلاعرسانی است و توصیه سرمایهگذاری نیست. هیچ هدف قیمتی یا توصیهای منتشر نمیشود.
About TickerBase · Data methodology & sources · Privacy · Terms